Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery

Collegeville, Pennsylvania (ots/PRNewswire) -

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced
today the signing of a definitive agreement under which it has
acquired Haptogen Ltd., a Scottish company based in Aberdeen that is
focused on the discovery of biopharmaceutical therapies. This
acquisition significantly increases Wyeth's already robust
biotechnology drug discovery capabilities.

"Haptogen brings to Wyeth a suite of next-generation biotechnology
discovery technologies that complement Wyeth's ongoing biotherapeutic
discovery efforts," says Frank Walsh, Ph.D., Executive Vice President
of Discovery, Wyeth Research. "In addition to the exciting technology
and first-rate research team that we are bringing into our
organization, we consider the opportunity to conduct
biopharmaceutical drug discovery in Scotland particularly important
because of the rich pool of scientific and technological talent."

Haptogen has developed a number of technologies that allow for the
discovery and optimization of protein therapeutics with significantly
improved profiles over the current generation of protein therapies.
Such benefits include the potential for more convenient routes of
administration as well as cell and organ penetration, opening the
opportunity to address diseases that are not treatable with the first
generation of protein therapeutics. Haptogen was founded in 2002 as a
spin-out of the University of Aberdeen, and its facilities are
located on the University of Aberdeen campus.

Through the acquisition, Haptogen becomes part of Wyeth Discovery
Research. In addition to Haptogen, Wyeth has a significant ongoing
research relationship in the field of translational medicine through
the Translational Medicine Research Collaboration. This partnership,
which was launched in 2006, includes Wyeth as well as the
Universities of Aberdeen, Edinburgh, Dundee and Glasgow, regional
National Health Service boards and Scottish Enterprise.

"Since Haptogen started its discussions with Wyeth, we have been
impressed by the quality and commitment of the people we have met,"
says Jim Reid, Founder and Chief Executive Officer of Haptogen Ltd.
"We believe that combining Haptogen's technology platforms with
Wyeth's existing discovery and development capabilities creates the
greatest opportunity for realizing the potential to bring new
treatments to patients."

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products
in the areas of women's health care, infectious disease,
gastrointestinal health, central nervous system, inflammation,
transplantation, hemophilia, oncology, vaccines and nutritional
products. Wyeth is the fourth largest biotechnology company in the
world in terms of marketed biotechnology products.

Wyeth is one of the world's largest research-driven pharmaceutical
and health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals,
vaccines, biotechnology products and non-prescription medicines that
improve the quality of life for people worldwide. The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare
and Fort Dodge Animal Health.

WYETH DISCLOSURE NOTICE: The statements in this press release that
are not historical facts are forward-looking statements based on
current expectations of future events and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include the inherent uncertainty of the timing and
success of, and expense associated with, research, development,
regulatory approval and commercialization of our products, including
with respect to our pipeline products; government cost-containment
initiatives; restrictions on third-party payments for our products;
substantial competition in our industry, including from branded and
generic products; data generated on our products; the importance of
strong performance from our principal products and our anticipated
new product introductions; the highly regulated nature of our
business; product liability, intellectual property and other
litigation risks and environmental liabilities; uncertainty regarding
our intellectual property rights and those of others; difficulties
associated with, and regulatory compliance with respect to,
manufacturing of our products; risks associated with our strategic
relationships; economic conditions including interest and currency
exchange rate fluctuations; changes in generally accepted accounting
principles; trade buying patterns; the impact of legislation and
regulatory compliance; risks and uncertainties associated with global
operations and sales; and other risks and uncertainties, including
those detailed from time to time in our periodic reports filed with
the Securities and Exchange Commission, including our current reports
on Form 8-K, quarterly reports on Form 10-Q and annual report on Form
10-K, particularly the discussion under the caption "Item 1A, RISK
FACTORS." The forward-looking statements in this press release are
qualified by these risk factors. We assume no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.

Web site: http://www.wyeth.com

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media: Michael Lampe, +1-484-865-1346, or Douglas Petkus,
+1-973-660-5218, or Investors: Justin Victoria, +1-973-660-5340, all
of Wyeth; Company News On-Call:
http://www.prnewswire.com/comp/044235.html